RBF Capital’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History

RBF Capital’s Portfolio SRRA Stock Details SRRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-411	Closed	-$6K	–	405
2019 Q3	$6K	Hold	411	–	–	﹤0.01%	385
2019 Q2	$9K	Hold	411	–	–	﹤0.01%	395
2019 Q1	$28K	Hold	411	–	–	﹤0.01%	384
2018 Q4	$22K	Hold	411	–	–	﹤0.01%	405
2018 Q3	$28K	Hold	411	–	–	﹤0.01%	406
2018 Q2	$51K	Sell	411 -209	-34%	-$21K	0.01%	387
2018 Q1	$49K	Hold	620	–	–	0.01%	370
2017 Q4	$93K	Hold	620	–	–	0.01%	350
2017 Q3	$39K	Hold	620	–	–	﹤0.01%	359
2017 Q2	$29K	Hold	620	–	–	﹤0.01%	355
2017 Q1	$38K	Buy	+620	New	+$36K	0.01%	359

Other funds holding SRRA

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Greenleaf Trust Kalamazoo, Michigan $10.4B AUM 0.97% 1-Year Est. Return

RBF Capital's SRRA Position: Q4 2019 in Review

RBF Capital sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q4 2019, closing a stake of 411 shares — an estimated $6K sold.

RBF Capital first reported a position in SRRA in Q1 2017 and held it in 11 quarters. The position peaked at $93K in Q4 2017. 29 funds tracked by Wall St. Rank hold SRRA as of Q4 2019.

RBF Capital reported no remaining Sierra Oncology, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
RBF Capital sold 411 Sierra Oncology, Inc. Common Stock shares in Q4 2019, an estimated $6K.
RBF Capital first reported a position in Sierra Oncology, Inc. Common Stock in Q1 2017 and held it in 11 quarters.
RBF Capital's Sierra Oncology, Inc. Common Stock position peaked at $93K in Q4 2017.
29 funds tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q4 2019.

Based on RBF Capital's 13F filing for Q4 2019, filed 13 Feb 2020.